FDA Slaps Full Clinical Hold on Aardvark’s Hunger Drug for Prader-Willi Syndrome
FDA pauses Aardvark’s PWS drug trials over safety concerns; studies stop, shares fall, talks with FDA ongoing.
/ 4 items
#AARD↓
Aardvark Therapeutics Pauses Phase 3 HERO Trial for PWS Hunger Drug ARD-101 Over Safety Signals
Aardvark Therapeutics voluntarily pauses Phase 3 HERO trial of ARD-101 for Prader-Willi hyperphagia after reversible cardiac signals in high-dose study. Updates expected Q2 2026.
Oppenheimer Starts Coverage on Aardvark Therapeutics with Strong Rating
Oppenheimer analyst gives Aardvark Therapeutics an Outperform rating with $35 price target, highlighting rare and common obesity drug programs and a key Phase 3 trial.
Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating
Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.